Nabilone
Alternative Names: CesametLatest Information Update: 02 Oct 2021
At a glance
- Originator Eli Lilly and Company
- Developer Bausch Health Companies; Valeant Pharmaceuticals International
- Class Antiemetics; Cannabinoids; Non-opioid analgesics; Small molecules
- Mechanism of Action Cannabinoid receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Nausea and vomiting
- Discontinued Fibromyalgia; Insomnia; Muscle spasticity; Neuropathic pain
Most Recent Events
- 13 Jul 2018 Valeant Pharmaceuticals International is now called Bausch Health Companies
- 01 Apr 2009 Nabilon is still in clinical development for Neuropathic pain in Canada
- 01 Apr 2009 No development reported - Phase-II for Insomnia in Canada (PO)